Physician profile
Sandy Ng
NPI 1356838411
$3,045.90
in general payments reported to CMS, 2019-2025
13 companies · $576 in 2025
The $576 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $147 · 2022: $298 · 2023: $896 · 2024: $1,130 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,601.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,396.64 | 2022-2024 | |
| Gilead Sciences, INC. | $410.92 | 2024-2025 | Epclusa |
| Medtronic, INC. | $317.10 | 2024 | Signia |
| Madrigal Pharmaceuticals | $255.43 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $161.22 | 2021-2024 | Gattex, Entyvio |
| Janssen Biotech, INC. | $117.47 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $110.79 | 2021 | |
| Mallinckrodt Hospital Products INC. | $86.42 | 2023-2024 | Terlivaz |
| Merck Sharp & Dohme LLC | $56.13 | 2021-2023 | Dificid |
| Ardelyx, INC. | $49.35 | 2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $45.09 | 2024-2025 | Voquezna |
| Lucid Diagnostics INC. | $24.32 | 2022 | |
| Amgen INC. | $15.02 | 2023 | Amjevita, Avsola |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandy Ng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.